Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Zhou

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Clinical Therapeutics|September 19, 2018
Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic ImpairmentVaishali Sahasrabudhe, Steven G Terra, Anne Hickman, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 26, 2019
A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
Vikas Kumar Dawra, Yali Liang, Haihong Shi, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2021
End-to-end application of model-informed drug development for ertugliflozin, a novel sodium-glucose cotransporter 2 inhibitorDaryl J Fediuk, Gianluca Nucci, Vikas K Dawra, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 22, 2024
Toward precision medicine: End-to-end design and construction of integrated microneedle-based theranostic systemsYiming Qin, Feiyun Cui, Yifei Lu, et al.
Journal of Clinical Pharmacology|April 4, 2021
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on ExposureJean-Claude Marshall, Yali Liang, Vaishali Sahasrabudhe, et al.
Clinical Pharmacology in Drug Development|June 18, 2019
Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual ComponentsVikas Kumar Dawra, Yali Liang, Hua Wei, et al.
Clinical Pharmacology in Drug Development|May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy SubjectsVikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
Clinical Pharmacology in Drug Development|November 15, 2018
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/MetforminVaishali Sahasrabudhe, Daryl J Fediuk, Kyle Matschke, et al.
AIDS Patient Care and Stds|June 28, 2012
Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008)Guoxing Greg Soon, Min Min, Kimberly A Struble, et al.
Clinical Pharmacology in Drug Development|June 21, 2019
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual ComponentsDaryl J Fediuk, Kyle Matschke, Yali Liang, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Clinical Therapeutics|September 19, 2018
Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic ImpairmentVaishali Sahasrabudhe, Steven G Terra, Anne Hickman, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 26, 2019
A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
Vikas Kumar Dawra, Yali Liang, Haihong Shi, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2021
End-to-end application of model-informed drug development for ertugliflozin, a novel sodium-glucose cotransporter 2 inhibitorDaryl J Fediuk, Gianluca Nucci, Vikas K Dawra, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 22, 2024
Toward precision medicine: End-to-end design and construction of integrated microneedle-based theranostic systemsYiming Qin, Feiyun Cui, Yifei Lu, et al.
Journal of Clinical Pharmacology|April 4, 2021
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on ExposureJean-Claude Marshall, Yali Liang, Vaishali Sahasrabudhe, et al.
Clinical Pharmacology in Drug Development|June 18, 2019
Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual ComponentsVikas Kumar Dawra, Yali Liang, Hua Wei, et al.
Clinical Pharmacology in Drug Development|May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy SubjectsVikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
Clinical Pharmacology in Drug Development|November 15, 2018
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/MetforminVaishali Sahasrabudhe, Daryl J Fediuk, Kyle Matschke, et al.
AIDS Patient Care and Stds|June 28, 2012
Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008)Guoxing Greg Soon, Min Min, Kimberly A Struble, et al.
Clinical Pharmacology in Drug Development|June 21, 2019
Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual ComponentsDaryl J Fediuk, Kyle Matschke, Yali Liang, et al.
Pageof 5